Beth Marsh is stepping into the role of Neurotech Pharmaceuticals’ chief commercial officer (CCO) beginning April 28. Marsh will lead the organization, particularly as it prepares for the US launch of ...

Researchers from the Czech Republic found that an AI system showed higher sensitivity and specificity for screening diabetic retinopathy compared to telemedicine evaluations.

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies ...

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies ...

Atsena Therapeutics announced in a press release that the FDA granted its gene therapy product candidate, ATSN-201, the regenerative medicine advanced therapy (RMAT) designation to treat X-linked ...

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications. The US Food and Drug ...

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies ...

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies ...

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies ...

Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic ...

The funding will help fund phase 1 and phase 2 proof-of-concept studies for lead candidates CTX203 and CTX114. Investigators advised clinicians of the potential for dystrophies that mimic age-related ...